Study guide
19.1 Amyloid, Sarcoid, and Other Infiltrative Disease Patterns
CCI Registered Cardiac Sonographer RCS
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: RCS Orientation and Clinical Context
1.1 RCS Identity, Exam Format, Application, and Retesting 1.2 Clinical History, Symptoms, Indications, and Risk Factors 1.3 Prior Studies, Serial Change, and Cross-Modality Context
2 Chapter 2: Orders, Safety, and Patient Preparation
2.1 Order Verification, Scope, and Protocol Selection 2.2 Sonographer Ergonomics and Staff Safety 2.3 Patient Preparation, Positioning, Consent, Infection Control, and Aftercare
3 Chapter 3: Reporting and 2-D TTE Foundations
3.1 Structured Findings, Significant Results, and Escalation 3.2 Standard 2-D TTE Windows, Views, and Acquisition Sequence 3.3 2-D Measurements, Foreshortening, Image Quality, and QA
4 Chapter 4: M-Mode and Doppler Acquisition
4.1 M-Mode Alignment, Timing, Measurements, and Pitfalls 4.2 Color Doppler Acquisition, Scale, Gain, and Jet Display 4.3 PW and CW Spectral Doppler Acquisition
5 Chapter 5: Advanced Doppler and Contrast
5.1 Tissue Doppler and Hemodynamic Sample Placement 5.2 Ultrasound-Enhancing Agents and LV Opacification 5.3 Agitated-Saline Studies and Intracardiac Shunts
6 Chapter 6: Stress Echocardiography
6.1 Exercise Stress Echo Protocols and Peak Imaging 6.2 Pharmacologic Stress Echo, Dobutamine, and Safety 6.3 Non-Ischemic Stress Echo and Hemodynamic Provocation
7 Chapter 7: TEE, Strain, and 3-D TEE
7.1 Assisting TEE: Preparation, Probe Safety, Views, and Complications 7.2 Strain Acquisition, Tracking Quality, and Reproducibility 7.3 3-D TEE Acquisition, Cropping, Orientation, and Artifacts
8 Chapter 8: 3-D TTE and the Aortic Valve
8.1 3-D TTE Full-Volume Acquisition and Quantitation 8.2 Aortic-Valve Anatomy, Morphology, and Function 8.3 Aortic Stenosis: Velocities, Gradients, Valve Area, and Flow States
9 Chapter 9: Aortic Regurgitation and Mitral Structure
9.1 Aortic Regurgitation Mechanisms and Integrated Severity 9.2 Mitral-Valve Anatomy, Motion, and Mechanisms 9.3 Mitral Stenosis: Planimetry, Gradients, Pressure Half-Time, and Suitability
10 Chapter 10: Mitral and Tricuspid Valve Findings
10.1 Mitral Regurgitation Mechanism, Quantitation, and Severity Integration 10.2 Tricuspid-Valve Anatomy, Structure, and Function 10.3 Tricuspid Stenosis Assessment
11 Chapter 11: Right-Sided Valve Disease
11.1 Tricuspid Regurgitation Mechanism and Severity 11.2 Pulmonic-Valve Anatomy, Structure, and Function 11.3 Pulmonic Stenosis Assessment
12 Chapter 12: Pulmonic Regurgitation and Prosthetic Valves
12.1 Pulmonic Regurgitation Mechanism and Severity 12.2 Normal Mechanical and Bioprosthetic Valve Assessment 12.3 Prosthetic Obstruction, Regurgitation, Thrombosis, and Patient–Prosthesis Mismatch
13 Chapter 13: Endocarditis and Cardiac Chambers
13.1 Valvular Endocarditis, Vegetations, Abscess, and Complications 13.2 LV and LA Size, Geometry, Volumes, Mass, and Function 13.3 RV and RA Size, Pressure, Volume, and Function
14 Chapter 14: Cardiomyopathy Phenotypes and Diastology
14.1 Dilated and Hypertrophic Cardiomyopathies, SAM, and LVOT Obstruction 14.2 Restrictive, Arrhythmogenic, and Stress Cardiomyopathies 14.3 Diastolic Function, Filling Pressure, Grading, and Pitfalls
15 Chapter 15: Systolic Function and Ischemia
15.1 LV Systolic Function, Simpson EF, Regional Motion, and Output 15.2 RV Systolic Function: TAPSE, S-prime, FAC, and Coupling 15.3 Ischemic Heart Disease, Coronary Territories, Stress Response, and Complications
16 Chapter 16: Pericardium and Great Vessels
16.1 Pericardial Effusion, Tamponade, Constriction, and Doppler Physiology 16.2 Great Vessels, Venous Return, and Pulmonary Artery Assessment 16.3 Aortic Root, Aneurysm, Dissection, and Coarctation
17 Chapter 17: Pulmonary Pressure, Masses, and Congenital Recognition
17.1 Pulmonary Hypertension, RAP/PASP Estimation, and RV Consequences 17.2 Cardiac Masses, Thrombus, Tumor, Vegetation, and Mimics 17.3 Adult Recognition of ASD, VSD, PFO, PDA, and Congenital Clues
18 Chapter 18: Devices, Strain, and Hemodynamics
18.1 ICDs, Pacemakers, Occluders, Closure Devices, and Mechanical Support 18.2 Strain Interpretation, Global Longitudinal Strain, and Disease Patterns 18.3 Cardiac Hemodynamics, Bernoulli, Continuity, Stroke Volume, and Shunts
19 Chapter 19: Infiltrative Disease and Physics Foundations
19.1 Amyloid, Sarcoid, and Other Infiltrative Disease Patterns 19.2 Ultrasound Wave Properties, Propagation, Frequency, and Wavelength 19.3 Artifact Recognition: Reverberation, Shadowing, Mirror, Refraction, and Aliasing
20 Chapter 20: Resolution and Doppler Optimization
20.1 Axial/Lateral Resolution, Frame Rate, Depth, Focus, and Trade-Offs 20.2 Spectral Doppler Optimization, Nyquist, Filters, Gain, and Angle 20.3 Color Doppler Optimization, Scale, Priority, Variance, and Gain
21 Chapter 21: 2-D, 3-D, and Contrast Optimization
21.1 2-D Optimization: Frequency, Gain, TGC, Harmonics, Depth, and Focus 21.2 3-D Optimization: Volume Rate, Stitching, Cropping, and Display 21.3 Contrast Optimization: Mechanical Index, Destruction, Replenishment, and Artifacts
19.1 Amyloid, Sarcoid, and Other Infiltrative Disease Patterns
Key Takeaways Explain This Topic AI
Echo identifies an infiltrative or storage phenotype through morphology, hemodynamics, deformation, RV and atrial involvement, valves, output, and effusion but does not establish final etiology.
Amyloid suspicion rises with increased wall thickness, low stroke volume, diastolic and tissue-velocity abnormalities, and relative apical sparing, yet echo cannot distinguish AL from ATTR.
Sarcoid is often patchy and may produce basal septal thinning, noncoronary regional dysfunction, aneurysm, or biventricular disease while an early TTE remains normal.
Hemochromatosis, Fabry and other storage disease, endomyocardial fibrosis, hypertension, AS, HCM, CKD, and artifact must be separated through careful acquisition and multimodality context.
Last updated: July 2026
Report an infiltrative phenotype, not an unproven etiology
Infiltrative and storage diseases alter myocardium through deposited protein, granulomatous inflammation, iron, abnormal metabolites, fibrosis, or endocardial injury. Echo may be the first clue, but overlapping hypertension, aortic stenosis, hypertrophic cardiomyopathy, chronic kidney disease, athletic remodeling, and obesity can produce similar wall thickening or dysfunction. Review age, blood pressure, valve disease, ECG voltage and conduction, heart-failure pattern, systemic disease, neuropathy, carpal tunnel history, malignancy, inflammatory symptoms, and prior imaging. The echo conclusion should describe the phenotype and degree of suspicion; laboratory testing, genetics, scintigraphy, CMR, PET, or tissue establishes etiology.
Acquire a complete study rather than chasing one signature. Measure LV wall thickness from a perpendicular parasternal plane at end-diastole, excluding RV trabeculation and moderator-band tissue from the septum. Quantify LV mass and volumes, LA and RA volumes, RV wall thickness, size and function, valve thickness and regurgitation, stroke volume, filling parameters, pulmonary pressure, and pericardial effusion. Obtain three nonforeshortened apical views for strain with stable ECG timing, adequate frame rate, and correct endocardial tracking. Preserve vendor, software, loading, rhythm, and image quality for serial work.
Recognize the amyloid constellation
Domain Common cardiac amyloid clue Limitation or mimic
Morphology Increased LV and often RV wall thickness, thickened valves or atrial septum, biatrial enlargement Hypertension, AS, HCM, CKD, and storage disease also increase thickness
Hemodynamics Progressive diastolic dysfunction, elevated filling pressure, low stroke-volume index despite preserved EF Rhythm, MR, loading, and age alter Doppler; early disease may be subtle
Tissue Doppler Markedly reduced mitral annular e′, a′, and s′ velocities Angle, annular calcification, tethering, pacing, and sampling error
Deformation Reduced GLS with relative apical sparing ESRD, HCM, AS, and technical tracking can mimic; not present in every case
Associated Small pericardial effusion, RV dysfunction, low-flow low-gradient AS Each feature is nonspecific alone
Relative apical sparing means apical longitudinal strain is less impaired, or more negative, than basal and mid strain. Confirm that the apex is not foreshortened and basal segments are tracked throughout systole. A bull's-eye color pattern is display dependent and should not be called diagnostic or used in isolation. GLS is load-, vendor-, frame-rate-, and tracking-dependent. EF may remain preserved while GLS and stroke volume fall because a thick-walled small cavity ejects a normal fraction of a reduced volume.
The older description of a sparkling myocardium is less specific with harmonic imaging and modern processing. Do not use brightness as a tissue diagnosis. Similar echo features occur in AL and transthyretin, or ATTR, amyloidosis; echo cannot distinguish the protein type. Light-chain evaluation and ATTR pathways carry different urgency and testing, so the sonographer should promptly flag a suspicious constellation without assigning subtype or treatment.
Contrast sarcoid's patchy phenotype
Cardiac sarcoidosis is granulomatous and often regionally heterogeneous rather than uniformly thick-walled. Echo may show focal wall thinning or thickening, particularly basal septal thinning, noncoronary regional wall-motion abnormalities, ventricular aneurysm, LV or RV dilation and systolic dysfunction, MR from papillary involvement or remodeling, pericardial effusion, and pulmonary-hypertension consequences. Conduction disease or ventricular arrhythmia may be the clinical clue even when TTE is normal.
No echo pattern excludes sarcoid, and sensitivity is limited in early or patchy disease. A regional abnormality should be confirmed in orthogonal planes to reject dropout, foreshortening, and coronary-territory ischemia. CMR detects scar and inflammation-related tissue patterns; FDG-PET assesses active inflammation under a dedicated preparation protocol. Those modalities, clinical criteria, and sometimes biopsy determine diagnosis. Echo contributes chamber function, hemodynamics, valve effects, and serial response, not a final inflammatory label.
Recognize other phenocopies and endocardial patterns
Disease process Possible echo phenotype Discriminator outside routine echo
Hemochromatosis Early diastolic dysfunction, later dilated or restrictive physiology and reduced biventricular function Iron studies and CMR tissue characterization
Fabry or other storage disease Concentric LV thickening, prominent papillary muscles, RV thickening, diastolic dysfunction, reduced regional or global strain Enzyme, genetic, renal, neurologic, and CMR evidence
Eosinophilic or endomyocardial fibrosis Apical endocardial thickening or obliteration, mural thrombus, restrictive filling, AV-valve regurgitation Blood, systemic, CMR, and sometimes tissue findings
Metastatic or inflammatory infiltration Focal or diffuse myocardial thickening, mass, dysfunction, or effusion Clinical cancer/inflammation context and multimodality imaging
Fabry disease is a storage phenocopy rather than amyloid deposition, and iron overload may progress from subtle relaxation change to chamber dilation. Apical obliteration must be distinguished from foreshortening and thrombus; use an ultrasound-enhancing agent under protocol when the border is uncertain. Restrictive filling describes hemodynamics, not etiology, and can occur in advanced myocardial, valvular, or pericardial disease.
Integrate discordant evidence
When wall thickness, ECG, strain, Doppler, and clinical data disagree, first verify measurements and loading. A hypertensive patient can still have amyloidosis; conversely, apical sparing does not erase severe AS or CKD. Report wall thickness and geometry, EF and stroke volume, GLS pattern and quality, diastolic evidence, atrial and RV involvement, valves, pressure, effusion, and interval change. Use language such as “findings raise suspicion for an infiltrative cardiomyopathy” and recommend clinical correlation through the interpreting physician. New severe dysfunction, low output, major effusion, or unstable arrhythmia requires prompt communication under laboratory policy.
Verify interval change
Before calling progression or treatment response, compare image plane, border convention, rhythm, blood pressure, loading, strain platform, and tracking quality. Reanalyze prior source images when a small change conflicts with the overall phenotype.
Apical sparing is a clue, not a diagnosis
Confirm nonforeshortened views and valid tracking, then interpret the strain pattern with wall thickness, stroke volume, Doppler, ECG, and clinical context. Amyloid subtype requires testing beyond echocardiography.